A smiling man with brown hair, wearing glasses and a light blue dress shirt, against a black background.

Jonathan E. Constance, PhD

Languages spoken: English

Academic Information

Departments Primary - Pediatrics

Divisions: Clinical Pharmacology

Board Certification

  • American Board of Clinical Pharmacology

Jonathan Constance, Ph.D., is a Research Assistant Professor in the Division of Clinical Pharmacology.

Dr. Constance’s research seeks to better understand patient level factors, such as genetics, stage of development, pathophysiologic states, and polypharmacy that influence drug efficacy and risk in neonatal and pediatric populations. Of special interest are the pharmacokinetic and pharmacodynamic relationships between concomitant antineoplastic therapy and non-anticancer medications related to altered chemotherapeutic activity and efficacy among pediatric patients with cancer. This encompasses interests in the ontogeny of xenobiotic metabolizing enzymes and transporters, patterns of drug use, and targeted therapies such as tyrosine kinase inhibitors and peptide/protein drugs. Using clinical data, including genetic characteristics, to inform in vitro drug-drug interaction models with the aim of understanding the consequences of interpatient variability on drug efficacy and toxicity.

Teaching and training professional and graduate students in Pharmacology and Toxicology and Pediatric Clinical Pharmacology.

Education History

Undergraduate University of Utah
 BS
Doctoral Training University of Utah
 PhD
Postdoctoral Fellowship University of Utah
 Clinical Fellow
Fellowship University of Utah
 Research Fellow

Selected Publications

Journal Article

  1. Biltaji E, Enioutina EY, Yellepeddi V, Rower JE, Sherwin CMT, Ward RM, Lemons RS, Constance JE (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leuk Lymphoma, 61(8), 1920-1931.
  2. Yellepeddi VK, Parashar K, Dean SM, Watt KM, Constance JE, Baker O (2021). Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. Clinical and translational science, 14(2), 683-691.
  3. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance J (2021). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. Journal of adolescent and young adult oncology, 10(2), 175-184.

News & Podcasts

Huntsman Cancer Institute News